Sunnybrook Health Science Centre

Running trials

• Recruiting

  Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT)

  NCT07191145· Phase 3· Sunnybrook Health Sciences Centre· Source

• Recruiting

  Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial

  NCT07454707· Phase 3· Sunnybrook Health Sciences Centre· Source

• Not yet recruiting

  A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

  NCT07861100· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Ketogenic Diet and Neuromodulation in Treatment Resistant Depression

  NCT07376018· Sunnybrook Health Sciences Centre· Source

• Not yet recruiting

  CEST for Prostate Biopsy

  NCT07785024· Sunnybrook Health Sciences Centre· Source

• Not yet recruiting

  Feasibility Evaluation of WEAR-IT for Hand Therapy After Stroke

  NCT07698067· Dr. Rosalie Wang· Source

• Recruiting

  Goal-Directed Therapy to Reduce Kidney and Cardiovascular Risk in Diabetic Kidney Disease (GOLD-STANDARD)

  NCT07434791· Sunnybrook Health Sciences Centre· Source

• Recruiting

  Optimized Recruitment to Drive Equitable Research in Stroke, Empowering Decision-making (ORDERed)

  NCT07576647· McMaster University· Source

• Recruiting

  ACT-GLOBAL IA Thrombolysis(ACT-REACT-004)Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632

  NCT07687056· Phase 3· University of Calgary· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Ted Rogers Understanding of Exacerbations in Heart Failure 2: Monitor

  NCT07447908· University Health Network, Toronto· Source

• Recruiting

  A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

  NCT07644559· Phase 2· Verastem, Inc.· Source

• Not yet recruiting

  Volunteer Facilitated Discharge Assistance and Supports at Home (DASH) for People With Stroke

  NCT07590076· Bruyère Health Research Institute.· Source

• Recruiting

  InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression

  NCT06781697· Phase 3· Sunnybrook Health Sciences Centre· Source

• Recruiting

  A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

  NCT07405801· Phase 2· Hoffmann-La Roche· Source

• Not yet recruiting

  A Dose Optimization Study of Enzalutamide in Elderly Patients With Advanced Prostate Cancer

  NCT07512076· Phase 2· Sunnybrook Health Sciences Centre· Source

• Recruiting

  Oral Versus Intramuscular Steroid Use to Control Rheumatoid Arthritis Flares

  NCT07245732· Phase 4· Sunnybrook Health Sciences Centre· Source

• Active, not recruiting

  Dose-dEscalated MR-Guided Radiotherapy for Localized Prostate Cancer

  NCT07674225· Sunnybrook Health Sciences Centre· Source

• Recruiting

  A Clinical Trial to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis.

  NCT07369076· Phase 1/2· Nura Bio· Source

• Not yet recruiting

  Sustained Mood Improvement With Laughing Gas Exposure

  NCT07262008· Phase 3· Women's College Hospital· Source

• Recruiting

  A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

  NCT07128199· Phase 3· Taiho Oncology, Inc.· Source

• Active, not recruiting

  A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

  NCT07170150· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Daily Temozolomide for Elderly Patients With Unmethylated MGMT- Promoter Newly Diagnosed GliOblatoma

  NCT07476794· Phase 2· Sunnybrook Health Sciences Centre· Source

• Active, not recruiting

  Recombinant Human Growth Hormone (rHGH) for Knee Osteoarthritis (KORR)

  NCT07036003· Phase 1/2· Dr. David Wasserstein· Source

• Recruiting

  Levetiracetam for Persons at Risk for Alzheimer's Disease

  NCT07477431· Phase 2· Sunnybrook Health Sciences Centre· Source

• Recruiting

  Analysis of Clinical Outcomes in Patients Undergoing Magnetic Resonance-Guided Focused Ultrasound for Medication-Refractory Tremor

  NCT07212244· Sunnybrook Health Sciences Centre· Source

• Recruiting

  The Multicentre Selective Lymphadenectomy Trial - 3

  NCT07049276· Melanoma Institute Australia· Source

• Active, not recruiting

  Study of COYA 302 for the Treatment of ALS

  NCT07161999· Phase 2/3· Coya Therapeutics· Source

• Recruiting

  A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT07164443· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of LY4257496 in Participants With Cancer (OMNIRAY)

  NCT07114601· Phase 1· Eli Lilly and Company· Source

• Recruiting

  rTMS for Youth Inpatients With Depression

  NCT07140575· Sunnybrook Health Sciences Centre· Source

• Recruiting

  Magnetic Resonance-Guided Focused Ultrasound Bilateral Capsulotomy for Refractory Anorexia Nervosa With Comorbid Obsessive Compulsive Disorder or Major Depressive Disorder

  NCT07113665· Phase 1· Sunnybrook Health Sciences Centre· Source

• Recruiting

  Using Cannabis to Treat Restless Legs Syndrome

  NCT06863740· Sunnybrook Health Sciences Centre· Source

• Recruiting

  Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  NCT06943755· Phase 2/3· Exelixis· Source

• Recruiting

  A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

  NCT06963827· Phase 3· Takeda· Source

• Recruiting

  Focused Ultrasound Neuromodulation in Patients With Treatment-Resistant Depression

  NCT07094789· Sunnybrook Health Sciences Centre· Source

• Recruiting

  Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

  NCT07177352· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Magnetic Resonance-Guided Focused Ultrasound Bilateral Capsulotomy for the Treatment of Refractory Bipolar Depression

  NCT07108257· Sunnybrook Health Sciences Centre· Source

• Recruiting

  Left Atrial Imaging Prior to Cardioversion: Leveraging Computed Tomography to Rule Out Thrombus in The Emergency Department (LA CLOTTED)

  NCT07002450· Ottawa Heart Institute Research Corporation· Source

• Recruiting

  Focused Ultrasound Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy

  NCT07179328· Phase 1· Sunnybrook Health Sciences Centre· Source

• Recruiting

  A Randomized Neuroimaging Trial of Psilocybin in Depression

  NCT06072898· Phase 2· Sunnybrook Health Sciences Centre· Source

• Recruiting

  Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.

  NCT06626022· Phase 3· University of Alberta· Source

• Recruiting

  Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2

  NCT07227246· Phase 3· Joseph Broderick, MD· Source

• Recruiting

  Life Following Excision of Neuroendocrine Tumors

  NCT06981455· Sunnybrook Health Sciences Centre· Source

• Recruiting

  A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

  NCT06827236· Phase 1/2· BioNTech SE· Source

• Active, not recruiting

  Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS)

  NCT07193953· Phase 1· Sunnybrook Health Sciences Centre· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

  NCT06790693· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  The HEROES Trial: Hyperbaric Oxygen Therapy for Endometriosis-Related Pain

  NCT06579040· Sunnybrook Health Sciences Centre· Source

• Recruiting

  Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

  NCT06801834· Phase 3· Gilead Sciences· Source

• Recruiting

  Accelerated vs. Conventional Theta Burst Stimulation for Late-life Depression

  NCT06854367· Centre for Addiction and Mental Health· Source

Showing 50 of 200.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer13 recruiting
• Depression12 recruiting
• Metastatic breast cancer12 recruiting
• Alzheimer disease11 recruiting
• Childhood cancers10 recruiting
• Stroke9 recruiting
• Head and neck cancer6 recruiting
• Atrial fibrillation5 recruiting
• Coronary artery disease4 recruiting
• Heart failure4 recruiting
• Lung cancer4 recruiting
• Melanoma4 recruiting
• ALS (motor neurone disease)3 recruiting
• Colorectal cancer3 recruiting
• Frontotemporal dementia3 recruiting
• Glioblastoma3 recruiting
• Neuroendocrine tumours3 recruiting
• Pancreatic cancer3 recruiting
• Vascular dementia3 recruiting
• Bipolar disorder2 recruiting
• Chronic kidney disease2 recruiting
• Gastric and oesophageal cancer2 recruiting
• High blood pressure2 recruiting
• Lewy body dementia2 recruiting
• Obstructive sleep apnoea2 recruiting
• Acute myeloid leukaemia1 recruiting
• Asthma1 recruiting
• Cervical cancer1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Endometrial cancer1 recruiting
• Endometriosis1 recruiting
• Essential tremor1 recruiting
• Hearing loss1 recruiting
• IgA nephropathy1 recruiting
• Migraine1 recruiting
• Myelodysplastic syndromes1 recruiting
• Obesity1 recruiting
• Osteoarthritis1 recruiting
• Ovarian cancer1 recruiting
• Parkinson disease1 recruiting
• Restless legs syndrome1 recruiting
• Rheumatoid arthritis1 recruiting
• Type 1 diabetes1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

  NCT06926660· Phase 2· Boehringer Ingelheim· Source

• Completed

  Study to Assess Function and Satisfaction of Oral Ubrogepant in Adult Participants After Multiple Migraine Attacks In Canada

  NCT06692881· AbbVie· Source

• Completed

  MED-EL Remote Care Multi-Center Feasibility Study

  NCT05973669· Med-El Corporation· Source

• Completed

  FET-PET/MRI Based Treatment Planning for Glioblastoma Multiforme in Post-Surgical Patients (FET-TREAT)

  NCT06451042· Sunnybrook Health Sciences Centre· Source

• Terminated

  Continuation Study for Latozinemab

  NCT06111014· Phase 3· Alector Inc.· Source

• Recruiting

  Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

  NCT05727176· Phase 2· Taiho Oncology, Inc.· Source

• Terminated

  Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

  NCT05860296· Phase 1/2· SignalChem Lifesciences Corporation· Source

• Terminated

  Nabilone for Agitation in Frontotemporal Dementia

  NCT05742698· Phase 2· Simon Ducharme, MD· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  TESTING -ON Post-Trial ObservatioNal Cohort Study

  NCT05434325· The George Institute· Source

• Terminated

  Anticoagulation Therapy Timing in Atrial Fibrillation After Acute and Chronic Subdural Hematoma

  NCT05472766· Sunnybrook Health Sciences Centre· Source

• Terminated

  A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada

  NCT05424562· AbbVie· Source

• Completed

  Single-Sided Deafness in the Medicare Population

  NCT05250414· Med-El Corporation· Source

• Completed

  Optina Diagnostics' Cerebral ß-Amyloid Status (CAS) Test

  NCT05107882· Optina Diagnostics Inc.· Source

• Terminated

  A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

  NCT05310071· Phase 3· Biogen· Source

• Completed

  Optimization of Prostate Biopsy - Micro-Ultrasound Versus MRI

  NCT05220501· Sunnybrook Health Sciences Centre· Source

• Completed

  Does Eliminating Coffee Avoid Fibrillation?

  NCT05121519· University of California, San Francisco· Source

• Completed

  Closed-loop Insulin Delivery In Type 1 Diabetes Pregnancies (CIRCUIT)

  NCT04902378· University of Calgary· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

  NCT04777396· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

  NCT04777409· Phase 3· Novo Nordisk A/S· Source

• Completed

  UNIty-Based MR-Linac Guided AdapTive RadiothErapy for High GraDe Glioma: a Phase 2 Trial

  NCT04726397· Sunnybrook Health Sciences Centre· Source

• Completed

  Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

  NCT04704219· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM

  NCT04440358· Phase 1/2· InSightec· Source

• Completed

  A Second Magnetic Resonance Guided Focused Ultrasound Thalamotomy for Essential Tremor

  NCT04720469· Sunnybrook Health Sciences Centre· Source

• Completed

  A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

  NCT04209855· Phase 3· AbbVie· Source

• Completed

  A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)

  NCT03987295· Phase 2· Alector Inc.· Source

• Completed

  EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)

  NCT03950076· Phase 4· Population Health Research Institute· Source

• Completed

  Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

  NCT03781063· Phase 2· Sermonix Pharmaceuticals Inc.· Source

• Completed

  Optimize PRO Study

  NCT04091048· Medtronic Cardiovascular· Source

• Completed

  Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer

  NCT03941093· Phase 3· Kyntra Bio· Source

• Completed

  POLESTAR Trial - An International Multi-center Early Discharge TAVI Program

  NCT03910751· Erasmus Medical Center· Source

• Completed

  ExAblate Blood-Brain Barrier Opening for Treatment of Alzheimer's Disease

  NCT03739905· InSightec· Source

• Completed

  Using Exercise and Electrical Brain Stimulation to Improve Memory in Dementia

  NCT03670615· Sunnybrook Health Sciences Centre· Source

• Completed

  Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption for Treatment of Glioma

  NCT03616860· InSightec· Source

• Completed

  A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)

  NCT03516981· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)

  NCT03599245· Phase 3· Hoffmann-La Roche· Source

• Completed

  Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

  NCT03517449· Phase 3· Eisai Inc.· Source

• Completed

  A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma

  NCT03126019· Phase 2· Incyte Corporation· Source

• Completed

  Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry

  NCT03048825· Phase 3· Population Health Research Institute· Source

• Completed

  Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

  NCT03268954· Phase 3· Takeda· Source

• Completed

  Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?

  NCT03269994· Phase 3· Memorial Sloan Kettering Cancer Center· Source

• Completed

  A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

  NCT03274492· Phase 3· Hoffmann-La Roche· Source

• Completed

  Novel Echocardiographic Methods for Early Identification of Neonates at Risk for Chronic Pulmonary Hypertension

  NCT04402645· Mount Sinai Hospital, Canada· Source

• Completed

  Alzheimer's Disease Neuroimaging Initiative 3

  NCT02854033· University of Southern California· Source

• Completed

  Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver

  NCT02724540· Phase 2· Abramson Cancer Center at Penn Medicine· Source

• Completed

  Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial

  NCT02168829· Phase 4· Ottawa Heart Institute Research Corporation· Source

• Recruiting

  JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

  NCT02468024· Phase 3· University of Texas Southwestern Medical Center· Source

• Completed

  A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion

  NCT02398656· Phase 3· University of Calgary· Source

• Withdrawn

  Improving Outcomes After Time Sensitive Prehospital Interventions: Rescu Epistry

  NCT04110912· Unity Health Toronto· Source

• Completed

  Amyloid and Glucose PET Imaging in Alzheimer and Vascular Cognitive Impairment Patients With Significant White Matter Disease

  NCT02330510· Dr. Sandra E Black· Source

Showing 50 of 57.

Conditions

Diseases this institution publishes on or runs trials for.

• Prostate cancer82 works · 27 trials
• Depression25 works · 12 trials
• Spinal cord injury21 works · 1 trial
• Metastatic breast cancer21 works · 15 trials
• Kidney cancer21 works · 1 trial
• Frontotemporal dementia19 works · 9 trials
• Neuroendocrine tumours19 works · 6 trials
• ALS (motor neurone disease)17 works · 9 trials
• Head and neck cancer15 works · 8 trials
• Myelodysplastic syndromes10 works · 4 trials
• IgA nephropathy4 works · 3 trials
• Restless legs syndrome3 works · 1 trial